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Abstract
Background and Purpose
In patients with myocardial infarction, ticagrelor reduces cardiovascular and sepsis-related
mortality, and can cause dyspnea. It is suggested that this is caused by adenosine receptor
stimulation, because in preclinical studies, ticagrelor blocks the nucleoside transporter and
increases cellular ATP release. We now investigated the effects of ticagrelor on the adeno-
sine system in humans in vivo.
Experimental Approach
In a double-blinded, placebo-controlled cross-over trial in 14 healthy subjects, we have
tested whether ticagrelor (180 mg) affects adenosine- and dipyridamole-induced forearm
vasodilation, as surrogates of nucleoside uptake inhibition and adenosine formation,
respectively. Also, ex vivo uptake of adenosine and uridine in isolated red blood cells was
measured. Primary endpoint was adenosine-induced vasodilation.
Key Results
Ticagrelor did not affect adenosine- or dipyridamole-induced forearm vasodilation. Also, ex
vivo uptake of adenosine and uridine in isolated red blood cells was not affected by ticagre-
lor. In vitro, ticagrelor dose-dependently inhibited nucleoside uptake, but only at supra-phys-
iological concentrations.
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Conclusion and Implications
In conclusion, at relevant plasma concentration, ticagrelor does not affect adenosine trans-
port, nor adenosine formation in healthy subjects. Therefore, it is unlikely that this mecha-
nism is a relevant pleiotropic effect of ticagrelor.
Trial Registration
ClinicalTrials.gov NCT01996735
Introduction
Ticagrelor is a novel direct-acting and reversibly binding P2Y12 receptor antagonist. In the
Platelet Inhibition and Patient Outcomes (PLATO) trial, the administration of ticagrelor to
patients with an acute coronary syndrome resulted in a striking reduction in the primary end-
point of death from vascular causes, myocardial infarction, or stroke compared to clopidogrel
[1]. Moreover, all cause mortality was reduced, and this was driven not only by vascular mor-
tality, but also by fewer deaths attributed to sepsis [2]. In addition, dyspnea and asymptomatic
ventricular pauses were reported more often in the ticagrelor treated patients. These finding
have instigated the search for pleiotropic effects of ticagrelor over and above the classical anti-
platelet effect.
In the past years, evidence is accumulating that ticagrelor inhibits the cellular uptake of the
endogenous nucleoside adenosine by blockade of the Equilibrative Nucleoside Transporter
(hENT1) [3]. Stimulation of membrane-bound adenosine receptors induces various beneficial
cardiovascular effects, including vasodilation, inhibition of platelet aggregation, inhibition of
inflammation, and increasing resistance against ischemia and reperfusion [4,5]. In addition,
intravenous administration of adenosine induces dyspnea and potently inhibits atrioventricu-
lar conductance [5,6]. Adenosine is mainly formed by intra- and extracellular dephosphoryla-
tion of AMP, which is catalyzed by 5’-nucleotidase. In contrast, degradation of adenosine in
humans is mainly confined to the intracellular compartment, by adenosine kinase and adeno-
sine deaminase. Consequently, in normal situations, the intracellular concentration is lower
than the extracellular concentration, and extracellular adenosine is rapidly taken up via the
hENT1 by surrounding cells, mainly red blood cells and endothelial cells [7]. Therefore, inhibi-
tion of the hENT1 activity will increase the extracellular adenosine concentration, and this
mechanism has been proposed to mediate the effects of ticagrelor observed in the PLATO
study [3].
Most of the current evidence on the effect of ticagrelor on adenosine metabolism is derived
from in vitro studies, or from studies in patients in which the adenosine metabolism could be
affected by other factors, such as co-medications. Therefore, in this study we aimed to test this
hypothesis in healthy humans in vivo. We used the vasodilator response to the local adminis-
tration of adenosine and to forearm ischemia as validated surrogates of adenosine uptake inhi-
bition, as previously described [8–11]. Furthermore, the vasodilator response to dipyridamole,
a potent inhibitor of hENT1, was used as a validated surrogate marker of endogenous adeno-
sine formation [12,13]. In addition, the effect of ticagrelor on adenosine and uridine uptake
was investigated directly in isolated red blood cells and whole blood.
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Methods
Subjects
The study protocol was in accordance with the Declaration of Helsinki and was approved by
the Institutional Review Board of the Radboud University Medical Center, Nijmegen, The
Netherlands. After approval, 15 healthy male volunteers signed written informed consent state-
ments before participation in the study, see also Fig 1. They had no history of cardiovascular
disease, bleeding tendency or asthma, and they were all non-smokers. Concomitant medication
was not permitted. In all participants a physical examination, electrocardiography, and labora-
tory investigation were performed to exclude cardiovascular and pulmonary disease, hyperten-
sion, diabetes mellitus, renal dysfunction, liver enzyme abnormalities, and thrombocytopenia.
Experimental protocol
The subjects were randomly assigned in a double-blinded cross-over design to a single dose of
ticagrelor 180 mg (Brilique, 2 tabs of 90 mg, AstraZeneca) or 2 fully mimicking placebos
Fig 1. Study Flow chart.
doi:10.1371/journal.pone.0137560.g001
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(Apotheek Haagse Ziekenhuizen, the Hague, the Netherlands). The experiments were per-
formed two hours after the intake of the study medication. The two experiments were sepa-
rated by at least 14 days. The randomization code was kept at the department of Clinical
Pharmacy of the Radboud University Medical Centre. The study medication was taken under
supervision at the Clininal Research Centre of our hospital.
This trial was prospectively registered at: clinicaltrials.gov (The effect of ticagrelor on the
adenosine system; NCT01996735).
Venous occlusion plethysmography
On the experimental days, we studied the subjects in supine position after an overnight fast. All
volunteers were asked to abstain from alcoholic drinks and caffeine-containing beverages for at
least 24 hours before the experiments. We performed the experiment in a temperature-con-
trolled room (24±1°C). A 27-gauge needle was inserted into the brachial artery of the non-
dominant arm for intra-arterial drug administration. We measured the forearm blood flow
(FBF) in both forearms simultaneously with venous occlusion plethysmography, using mer-
cury-in-silastic strain gauges and an occluded hand circulation as described previously [14].
The total intra-arterial infused volume was kept at a constant rate of 50 μL/min per dL of fore-
arm volume. Thirty minutes after cannulation of the brachial artery, we started the infusion of
normal saline at the calculated rate with concomitant measurement of the FBF. Normal saline
(baseline) and the dosages of the intra-arterial administered drug were infused for 5 minutes.
We performed four experiments, starting two hours after intake of the study medication,
which were all separated by a wash-out period of 30 minutes to prevent any cross-over effects.
Fig 2 provides a schematic overview of the experiment.
1. We measured FBF during the administration of 4 incremental dosages of adenosine into the
brachial artery. The dosages (0.15, 0.5, 1.5, and 5.0 μg/min/dL forearm volume) are similar to
a previous study in which we demonstrated a significant potentiation of adenosine-induced
Fig 2. Schematic flow chart of the experiment.
doi:10.1371/journal.pone.0137560.g002
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vasodilation by the ENT inhibitor dipyridamole and draflazine [9,10]. Adenosine-induced
forearm vasodilation is the primary endpoint of our study. Secondary endpoints include.
2. The blood flow response to 2 and 5 minutes of forearm ischemia was measured (post-occlu-
sive reactive hyperemia; PORH). Forearm ischemia was induced by inflation of an upper
arm cuff to 200 mmHg, as described previously [14]. We have previously demonstrated that
dipyridamole potentiates the PORH response [8] and that statins potentiate the PORH by
an increase of the extracellular adenosine formation [15].
3. Subsequently, FBF was measured during intra-arterial administration of dipyridamole (30
and 100 μl/min/dL forearm volume, which we also used in previous studies [11]). Dipyrida-
mole induces vasodilation by ENT inhibition, thereby increasing the extracellular adenosine
concentration at a rate proportionate to extracellular adenosine formation.
4. Finally, we measured the FBF response to the administration of acetylcholine (0.5 and
2.0 μg/min/dL forearm volume) to exclude nonspecific effects on vascular reactivity.
Blood sampling
Before intake of the study medication blood was drawn from an intravenous cannula in the
dominant arm for the determination of the plasma ticagrelor and caffeine concentration, and
for the ex vivo ENT transport measurements in isolated red blood cells. This measurement was
repeated approximately 2 hours after the ingestion of the study medication and just before
measurement of the vasodilator response to adenosine. Finally, the ticagrelor concentration
was determined before intake of the ticagrelor dose, 2 hours after the intake, and subsequently
before the start of each forearm blood flow experiment.
Analytic procedures
We determined plasma caffeine concentrations using reversed-phase HPLC with ultraviolet
detection set at 273 nm, according to Schreiber-Deturmeny and Bruguerolle [16]. In isolated
red blood cells, the uptake of adenosine and uridine was determined as described previously
[17]. In contrast to adenosine, uridine is not metabolized inside the cells, and therefore, uridine
uptake is a more direct measure of ENT activity than adenosine uptake [18]. Ticagrelor con-
centrations were determined by LC-MSMS. Liquid chromatographic separation was performed
at a temperature of 30°C with a mobile phase, consisting of solvent A (10 mM ammonium ace-
tate in water) and solvent B (acetonitrile). For the mass spectrometric analysis, heated electro-
spray ionization (HESI) was operated at a spray voltage of -2.5kV, a capillary temperature of
225°C and a vaporizer temperature of 382°C. Argon was used as collision gas at a pressure of
1.5 mTorr. Negative ion mode was used with selected reaction monitoring (SRM) for the quan-
titative analysis of ticagrelor. The most abundant product ion was used for quantification. The
quantification was performed using peak areas.
In vitro experiments
In isolated red blood cells from healthy volunteers not taking any medication, the effect of tica-
grelor on uridine uptake was measured as described previously (17). Briefly, uridine was added to
washed red blood cells to obtain a final concentration of 1000 μM. The cells were pre-incubated
with increasing concentrations of ticagrelor for ten minutes before the addition of uridine. After
3 seconds, uridine uptake was completely blocked by the addition of 10 μMdipyridamole and the
amount of uridine in the cell was determined using HPLC with UV detection set at 254 nm.
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Because of the high protein binding of ticagrelor of 99.8%, we also performed whole blood
experiments, in which ticagrelor was added to 1 ml of whole blood for 10 or 60 minutes.
Next, the red blood cells were isolated by centrifugation and uridine was added as described
above.
To measure the rate of disappearance of adenosine in the physiological situation, which is
the overall result of uptake and intracellular degradation, we added 1 μM of adenosine to 1 ml
of whole blood at 37°C, as previously described by Bonello et al [19]. After 0, 15, 30, 45, and 60
seconds, the transport, formation, and degradation of adenosine was completely blocked by a
adding an equal volume of pharmacological blocking solution, including NaCl (118mM); KCl
(5 mM); Na2EDTA (13.2 mM); dipyridamole (40 μM); iodotubercidin (ITU; 10μM); EHNA
(10μM); forskolin (11.5μM), and IBMX (115μM). After centrifugation the adenosine concen-
tration was measured in the supernatant using LC-MSMS. Separation was performed with a
Acquity UPLC HSS column. The mobile phase, consisting of solvent A (1 mM ammonium
fluoride in water) and solvent B (methanol). For the mass spectrometric analysis, heated elec-
trospray ionization (HESI) was operated at a spray voltage of +3kV, the capillary temperature
and the vaporizer temperature were set at 300°C. Argon was used as collision gas at a pressure
of 1.5 mTorr. Positive ion mode was used with selected reaction monitoring (SRM) for the
quantitation. The following SRM transitions were used:m/z 268.1(parent ion) tom/z 119.0
and 136.1 (both product ions).
Statistical analysis
The study was powered to detect a difference in the primary endpoint of adenosine-induced
vasodilation. The sample size calculation was based on the following assumptions: in previous
studies from our own group, we found that the vasodilator response to the intrabrachial
administration of adenosine averages 2.8±0.6, 4.4±1.0, 9.0±1.7 ml/min per dl of forearm vol-
ume for 0.5, 1.5, and 5.0 μg/min/dl, respectively (mean±SEM, n = 8). The pooled CV is 0.6, so
after log transformation the SD averaged 0.55. We expect that a (relative) difference between
the treatments is independent of the adenosine dose. Hence, a linear mixed model will be used,
with fixed factors treatment (ticagrelor vs placebo), adenosine dose, and period. Based on a cor-
relation of 0.7 between the measurements for all doses and time points and an SD of 0.55, the
SD of the contrast is 0.25. As a result, 13 evaluable subjects are needed to demonstrate an aug-
mentation of adenosine-induced vasodilation with 1.25 (ie a 25% increase) with a power of
80% and a two-sided alpha of 0.05. To account for one drop-out, we aim to include 14 healthy
volunteers.
FBF analyses were done offline before unblinding of the study. Mean FBF values were calcu-
lated from the FBF responses to the different stimuli. We calculated the average FBF during
last 4 minutes of the baseline FBF (normal saline), the last 2 minutes of the FBF response to
adenosine, dipyridamole and acetylcholine, and the first 3 minutes of the PORH. Results are
expressed as the median absolute FBF (mL/dL/min) with interquartile range (25–75%), unless
otherwise stated.
A linear mixed model was used to compare the FBF results of both experiments, with the
log FBF during placebo and ticagrelor treatment as the dependent variable, and treatment
(ticagrelor versus placebo), adenosine dose, and period as fixed factors. We used a heteroge-
neous compound symmetry as the type of repeated covariance. A carry over effect was
excluded calculating the interaction between ‘sequence’ and the primary endpoint in the
mixed model analysis. For uridine uptake experiments, sigmoidal dose response curves were
constructed with a variable slope and IC50 were calculated for each series of experiments,
using GraphPad Prism.
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Results
Subjects
23 subjects were screened for eligibility. Four participants withdrew from participation and 4
participants were excluded, because of drug abuse, a history of asthma, a platelet count of
145109/L, and a systolic heart murmur. Insertion of the arterial needle failed in 1 subject and
this subject was replaced. Due to repeated dislocation of the intra-arterial needle, we had to dis-
continue the experiment after the infusion of dipyridamole during a single visit in another sub-
ject. Thus, 13 fully evaluable subjects were included and one subject in whom acetylcholine
responses were lacking during one (placebo) visit, see also Fig 1.
The baseline characteristics are depicted in Table 1. The plasma caffeine concentration
was< 1 mg/L in all subjects, showing adequate caffeine restriction. The ticagrelor concentra-
tion averaged 1.18±0.13, 1.01±0.11, 0.90±0.09, and 0.80±0.08 μM (mean±SE) at 2, 3, 4, and 4.5
hours after ticagrelor intake, respectively (see Fig 2 for the time points).
Venous occlusion plethysmography
Baseline FBF in the experimental forearm was 1.2 (0.9–1.8) and 1.35 (0.9–1.7) mL/dL/min dur-
ing placebo and ticagrelor, respectively. There was no significant carry-over effect in this study
(P = 0.58). Intrabrachial administration of adenosine significantly increased FBF in the experi-
mental forearm, but not in the control forearm (P<0.01; Fig 3A). Pretreatment with ticagrelor
did not potentiate adenosine-induced vasodilation: the incremental dosages of adenosine
increased the FBF to 1.3 (0.9–1.6), 1.8 (1.4–2.6), 3.6 (2.0–4.1), and 6.3 (4.9–9.2) mL/dL/min
during placebo, and to 1.3 (1.2–1.6), 2.3 (1.5–3.6), 4.5 (2.4–7.8), and 9.0 (5.5–17.2) mL/dL/min
after ticagrelor administration (P = 0.33; Fig 3A). Furthermore, we did not see any correlation
between the plasma ticagrelor concentrations and the area under the curve for adenosine-
induced FBF (Spearman correlation coefficient -0.13, P = 0.67; Fig 4).
Baseline FBF before arterial occlusion was 1.5 (0.8–3.0) mL/dL/min during placebo and 1.5
(0.6–1.9) ml/dl/min during ticagrelor treatment. The hyperemic response after 2 minutes of
arterial occlusion was 7.9 (5.1–11.8), 1.2 (0.8–2.3), and 1.5 (1.0–3.1) during placebo and 8.1
(5.6–9.2), 1.4 (0.6–2.2), and 1.6 (0.8–2.0) during ticagrelor in the 1st, 2nd and 3rd minute respec-
tively (p = 0.96 for the effect of ticagrelor) (Fig 3B).
Table 1. Baseline characteristics (means ± SD; n = 14).
Characteristic Value
Age (years) 22.1 ± 2.2
Blood pressure (mmHg)
Systolic 125 ± 7
Diastolic 67 ± 10
Heart rate (bpm) 62 ± 10
BMI (kg/m2) 22.3 ± 1.9
Blood plasma values
Platelet count (*109/L) 230 ± 31
Creatinine (μmol/L) 80 ± 7
Non-fasting glucose (mmol/L) 5.1 ± 0.7
ALAT (U/L) 29 ± 14
Non-fasting cholesterol (mmol/L) 3.9 ± 0.7
doi:10.1371/journal.pone.0137560.t001
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After 5 minutes of arterial occlusion, the hyperemic response was 15.2 (11.1–23.7), 3.1 (1.6–
5.1), and 1.6 (1.1–3.3) mL/dL/min during placebo and 14.1 (11.5–20.3), 2.7 (1.9–5.6), and 2.1
(1.4–3.7) mL/dL/min in the 1st, 2nd and 3rd minute respectively (p = 0.20 for effect of ticagrelor;
Fig 3C).
Comparable to adenosine, intrabrachial administration of dipyridamole significantly
increased FBF in the experimental forearm but not in the control forearm (P<0.01, Fig 3D).
Again, the vasodilator response to dipyridamole did not differ between placebo and ticagrelor
treatment. The FBF in the experimental forearm was 1.2 mL/dL/min (0.9–2.6) at baseline and
1.9 (1.1–4.1) and 2.7 (1.8–6.1) during administration of the two doses of dipyridamole after
treatment with placebo, versus 1.3 (0.9–2.0), 2.3 (1.4–3.6), and 3.2(1.5–4.8) after treatment
with ticagrelor (p = 0.29 for effect of ticagrelor, Fig 3D).
Similarly, ACh-induced vasodilation did not differ between both experiments. The FBF at
baseline and during administration of the two doses of acetylcholine was 3.5 mL/dL/min
(2.0–5.3), 10.8 (7.8–19.1), and 17.3 (12.5–31.2) after treatment with placebo, versus 3.9
Fig 3. Forearm blood flowmeasurements. FBF values in the experimental forearm (triangle) and non-experimental forearm (circle) after ticagrelor
treatment (black symbols) or placebo treatment (open symbols, dashed line) during intrabrachial administration of adenosine (A), after five (B) and two (C)
minutes of forearm ischemia, and during intrabrachial administration of dipyridamole (D). P-values represent the effect of ticagrelor on the FBF-values.
doi:10.1371/journal.pone.0137560.g003
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(3.0–6.5), 8.1 (4.4–19.3), and 16.8 (10.4–28.6) after treatment with ticagrelor (p = 0.11 for effect
of ticagrelor).
Ex vivo nucleoside uptake inhibition
Red blood cells were isolated from blood samples taken before and 2 hours after intake of the
study drug. The uptake of adenosine in these cells was not affected by oral ticagrelor, when
compared to baseline (P = 0.87; Fig 5A). Uridine uptake was inhibited by an average of 11%,
but this did not reach statistical significance (P = 0.056) (Fig 5B).
In vitro nucleoside uptake inhibition
In isolated red blood cells, ticagrelor dose-dependently inhibited uridine uptake with an IC50
value of 3.010−7 M (95% CI 2.010−7 to 4.510−7, n = 3; Fig 6A). In the experiments in which
ticagrelor was added to whole blood before isolation of the red blood cells, the IC50 of ticagrelor
for uridine uptake inhibition was 7.310−6 M (95% CI 6.010−6 to 1.310−5, n = 3; Fig 6B). In
addition, in whole blood, the disappearance of adenosine was only inhibited significantly by
the highest concentration of ticagrelor used (10−4 M) (n = 2; Fig 6C).
Discussion & Conclusions
The main finding of our study is that in healthy subjects a single dose of 180 mg of ticagrelor
does not potentiate the forearm vasodilator response to adenosine, nor post-occlusive reactive
hyperemia and dipyridamole-induced vasodilation. In addition, we observed no significant ex
vivo nucleoside uptake inhibition in isolated red blood cells in these subjects after oral treat-
ment with ticagrelor. These in vivo and ex vivo findings are consistent with additional in vitro
Fig 4. The correlation between the plasma ticagrelor concentration and the area under the curve
(AUC) of adenosine-induced forearm vasodilation.
doi:10.1371/journal.pone.0137560.g004
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studies in isolated red blood cells demonstrating that ticagrelor only inhibits nucleoside trans-
port in concentrations that are considerably higher than those obtained after normal dosing.
Together, our findings argue against a role for increased adenosine receptor stimulation as a
relevant pleiotropic effect of ticagrelor.
In the last few years, several papers suggest that ticagrelor increases the extracellular concen-
tration of endogenous adenosine and it is speculated that this contributes to the effects of tica-
grelor that are observed in clinical studies that cannot easily be explained by platelet
aggregation inhibition, including reduced mortality, dyspnea, ventricular pauses, limitation of
myocardial infarct size, and effects on inflammation [3,20]. Adenosine induces various effects
by stimulation of membrane-bound adenosine receptors, including direct vasodilation, platelet
aggregation inhibition, modulation of sympathetic nervous system activity, modulation of
inflammation, and limitation of (myocardial) ischemia and reperfusion injury [4,5]. In addi-
tion, the intravenous administration of adenosine has negative dromotropic effects on the
heart, and induces a sensation of dyspnea [5,6].
Previous in vitro studies have demonstrated two different effects of ticagrelor on adenosine
metabolism: first, ticagrelor augments the release of adenosine triphosphate (ATP), which acts
as a precursor for extracellular adenosine formation, from isolated red blood cells, with an IC50
value of 14 μM [21]. Secondly, ticagrelor inhibits adenosine uptake via the ENT with a reported
IC50 value of 100–260 nmol/l [22,23]. It needs to be emphasized, however, that these experi-
ments were performed in isolated cells without plasma. Given the> 99% plasma protein bind-
ing of ticagrelor in human blood, these IC50 values cannot easily be compared to the whole
blood ticagrelor concentration of 0.5–1.5 μM observed during normal dosing in patients. Tica-
grelor does not have a direct effect on adenosine receptors itself, does not affect the breakdown
of adenosine by adenosine deaminase, nor is it converted into adenosine [19].
Our experiment was designed to investigate both the effect of ticagrelor on adenosine
uptake as well as the effect of ticagrelor on extracellular adenosine formation (e.g. by increased
ATP release). Direct measurement of the extracellular adenosine concentration is technically
highly demanding given the extremely short half-life of adenosine and there is great contro-
versy about the normal extracellular concentration in human plasma [24]. Therefore, we used
well-validated surrogates of extracellular adenosine formation and uptake. In the absence of
Fig 5. Ex vivo uptake of adenosine (A) and uridine (B) in red blood cells isolated from the subjects before (pre-tica) and two hours after intake of
ticagrelor (post-tica). In A, the adenosine concentration in the supernatant is expressed as the percentage of the baseline adenosine concentration (n = 13;
P >0.1). In B, the uridine uptake is expressed for each individual subjects before and after intake of ticagrelor (n = 13, P = 0.056 for comparison between
before and after).
doi:10.1371/journal.pone.0137560.g005
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any effects of ticagrelor on adenosine receptors or adenosine degradation, the vasodilator
response to the intrabrachial administration of adenosine is a well-validated surrogate of aden-
osine transporter function, as we have previously described [9,10]. We also studied PORH
because this is mediated, at least in part, by an increased endogenous formation of adenosine
[8]. Dipyridamole is a potent hENT1 blocker and increases the extracellular adenosine concen-
tration at a rate proportional to the extracellular formation of adenosine, as demonstrated pre-
viously [12]. We did not observe an effect of ticagrelor on any of these stimuli, demonstrating
that there is no relevant increase in extracellular adenosine formation and adenosine transport.
Nonspecific effects of ticagrelor on vascular reactivity were ruled out using acetylcholine-
induced vasodilation. Consistent with these in vivo findings, there was no significant inhibition
of ex vivo adenosine uptake in red blood cells, isolated before and after ticagrelor-intake. Uri-
dine uptake was inhibited with 11%, but this did not reach statistical significance (P = 0.056).
For the interpretation of these results, it is important to realize that after facilitated diffusion
via the ENT, adenosine is rapidly metabolized, and that intracellular deamination of adenosine
Fig 6. In vitro uptake of uridine in isolated red blood cells from healthy subjects. The cells were pre-incubated with ticagrelor either after isolation (A;
n = 3) of in whole blood before isolation of the red blood cells (B; n = 3). In C, the adenosine disappearance in whole blood from healthy volunteers is
expressed as the percentage of the baseline concentration in the presence of ticagrelor in the concentrations 10−6 M (squares), 10−5 M (triangles), and 10−4
M (reversed triangles or in the presence of vehicle (circles, dashed line) (n = 2).
doi:10.1371/journal.pone.0137560.g006
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is rate limiting for adenosine uptake rather than ENT activity [25]. Only after pharmacological
inhibition of>80% of ENT activity, the ENT transporter becomes rate limiting, and adenosine
uptake is reduced [25]. As such, 11% ENT inhibition will not have any effect on extracellular
adenosine concentration. Indeed, also in whole blood experiments, ticagrelor did not affect
adenosine disappearance at relevant concentrations.
The results of our series of experiments contradict previous studies. In vitro Van Giezen
et al reported in a canine model that ticagrelor augmented adenosine-induced vasodilation in
the coronary artery [22]. However, this effect was observed only at a ticagrelor plasma concen-
tration of 13.4 μM and not with the lower concentration of 4.1 μM, which is still considerably
higher than the plasma concentration in patients treated with ticagrelor. In contrast, in another
in vitro study, the addition of 1 μM of ticagrelor to whole blood resulted in a slightly but signifi-
cantly higher adenosine concentration 1 minute after the addition of 7.1 μM of adenosine [26].
In healthy subjects in vivoWittfeldt et al showed that a single dose of 180 mg of ticagrelor aug-
mented the coronary blood flow velocity after intravenous adenosine infusion, which was pre-
vented by concomitant administration of the adenosine receptor antagonist theophylline [27].
Similar results were obtained by Alexopoulos et al in patients with a recent non-ST-elevation
acute coronary syndrome [28]. The route of administration in these studies is the major and
important difference with our study: in our model adenosine is administered into the brachial
artery, resulting in a high local arterial adenosine concentration, but without any systemic
effects. Intravenous administration of adenosine, however, induces major systemic hemody-
namic effects consisting of increased systolic blood pressure and heart rate and decrease of dia-
stolic blood pressure by the combination of a direct vasodilator effect and a pronounced
activation of sympathetic nervous system activity by stimulation of peripheral chemoreceptors
[29]. Therefore, the coronary blood flow response in the Wittfeldt and Alexopoulos papers is
driven by different effects, whereas adenosine-induced vasodilation in our study was not con-
founded by systemic hemodynamic and nervous effects. Finally, the plasma concentration of
ticagrelor in the study by Wittfeldt et al was slightly higher than in our study, despite the fact
that in both studies the plasma concentration was determined 2 hours after intake of 180 mg
ticagrelor in healthy subjects. Bonello et al measured plasma adenosine concentration in
patients with an acute coronary syndrome who were randomized to either ticagrelor or clopi-
dogrel at a time point of 6 hours after the loading dose [19]. They observed a significantly
higher adenosine concentration in the patients treated with ticagrelor, and they observed a sig-
nificant inhibition of ex vivo adenosine uptake in whole blood. It is likely that in the patients in
this study, just as in the study by Alexopoulos et al, the adenosine metabolism is affected by the
myocardial ischemia, the profound activation of the sympathetic nervous system by the coro-
nary event, and by the comedication (e.g. statins that will increase the extracellular formation
of adenosine by activation of the ecto-5’-nucleotidase [12,15]). In addition, the pharmacologi-
cal blocking solution that is used to completely block adenosine metabolism in the ex vivo
whole blood experiments differs from the solution that we previously have validated to result
in a almost complete recovery of adenosine [24]. The inconsistent results of our study and the
Bonello study might be caused, at least in part, by these differences.
Study limitations
Our study has several potential limitations. First, our experiments were performed in healthy
subjects without cardiovascular disease and without concomitant cardiovascular drugs, such as
in the study by Bonello et al [19]. Therefore, the results of our study do not exclude any effect
of ticagrelor on the adenosine system in patients with acute coronary events. Secondly, we
investigated adenosine formation and uptake in the forearm, in contrast to the coronary
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circulation that was studied by Wittfeldt et al [27]. However, ENT is not known to differ
between heart and forearm and therefore we believe that extrapolation from forearm to heart is
valid for this particular research question.
Conclusions
Ticagrelor dose-dependently inhibits nucleoside transporter activity in isolated red blood cells
of healthy volunteers. However, the plasma concentration of ticagrelor after normal dosing in
humans is too low to result in a significant increase in extracellular adenosine and adenosine
receptor stimulation via this mechanism. In addition, the lack of any effect of ticagrelor on
dipyridamole-induced vasodilation suggests that ticagrelor does not augment endogenous
extracellular adenosine formation. Our findings, therefore, argue against a role these mecha-
nisms as an explanation for the effects of ticagrelor, including lower mortality, dyspnea, ven-
tricular pauses, and modulation of inflammation, as observed in recent clinical studies.
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